Switzerland's Pharvaris Q2 loss narrows, cash rises to €318 mln

Pharvaris

12/08/2026 12:02

Overview
Switzerland biopharma firm reported Q2 loss per share of €0.70, improving from prior year
Cash and equivalents rose to €318 mln, with runway extended into 2028 after $132 mln offering
R&D and G&A expenses increased as late-stage clinical programs advanced

Outlook
Pharvaris expects topline data from CHAPTER-3 Phase 3 study in 3Q2026
FDA review of deucrictibant IR NDA ongoing, with PDUFA date set for April 23, 2027
Company says cash runway extends into 2028 following recent financing

Result Drivers
PIPELINE ADVANCEMENT - Higher R&D expenses attributed to progress in pivotal Phase 3 studies and regulatory filings for deucrictibant
PRE-COMMERCIAL ACTIVITIES - Increased G&A spending linked to preparations for potential U.S. launch and expanded organizational structure

Company press release: ID:nGNX8XGTXk

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
EUR 0.70
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Pharvaris N.V. is $46.00, about 33.6% above its August 11 closing price of $34.42

Reuters Recommended Reads
Aug 10 - Switzerland's MoonLake Q2 net loss narrows as expenses fall
Aug 11 - UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Aug 11 - Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)